Compare ETB & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Current Price
| Metric | ETB | PRTC |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.2M | 386.7M |
| IPO Year | N/A | N/A |
| Metric | ETB | PRTC |
|---|---|---|
| Price | $15.22 | $16.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 71.8K | 4.7K |
| Earning Date | 01-01-0001 | 08-28-2025 |
| Dividend Yield | ★ 8.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.65 |
| Revenue Growth | N/A | ★ 1265.60 |
| 52 Week Low | $11.59 | $13.30 |
| 52 Week High | $14.08 | $23.69 |
| Indicator | ETB | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 44.72 |
| Support Level | $15.17 | $16.42 |
| Resistance Level | $15.37 | $16.83 |
| Average True Range (ATR) | 0.19 | 0.28 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 81.32 | 30.20 |
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.